(ACIU) AC Immune S.A. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ACIU) AC Immune S.A. Complete Analysis Pack
See the Bigger Picture
This AC Immune S.A. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. This page already shows a real preview of the report content, so you can review the format and analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
ACI-24.060 Phase 2
ACI-24.060 is AC Immune S.A.'s anti-Abeta active immunotherapy and its most clinically advanced vaccine program. It is in Phase 2 for Alzheimer's disease and is also being evaluated in Down syndrome, giving it a broad proof-of-concept path across two Abeta-driven indications. In BCG terms, it fits a Star: high-growth market, high strategic value, and meaningful upside if the Phase 2 readout is strong.
ACI-35.030 Phase 2
ACI-35.030 is AC Immune S.A.'s anti-phospho-Tau vaccine and moved from phase 1b into phase 2, which supports its Star status in a high-growth tau-targeting Alzheimer's disease field. Tau-directed R&D is one of the most active parts of AD drug development, with late-stage clinical proof still scarce, so phase 2 data can matter a lot. The program gives AC Immune a shot at a larger future market if efficacy holds.
PI-2620 Tau PET
PI-2620 Tau PET is AC Immune S.A.'s 18F tau imaging tracer and a Star asset in its BCG mix. Partnered with Life Molecular Imaging, it helps detect tau pathology, a key biomarker in Alzheimer’s and other neurodegenerative disease programs. Its value comes from direct use in patient selection, diagnosis, and drug-readout studies across tau-focused trials.
Crenezumab Prevention Trial
Crenezumab is a humanized anti-Abeta monoclonal antibody that AC Immune S.A. studied in phase 2 Alzheimer’s prevention work, making it one of the company’s best-known late-stage assets. It targets amyloid-beta, the core plaque protein in Alzheimer’s. For BCG terms, it fits "Stars" only if the program can still drive visible pipeline value and future partnering interest.
- Humanized anti-Abeta antibody
- Phase 2 prevention study
- Late-stage, high-visibility asset
Tau Franchise
AC Immune S.A.'s Tau Franchise is its strongest growth engine, spanning tau vaccines, imaging, and small molecules across Alzheimer's disease and other tauopathies. Tau is a top therapeutic target because tau pathology tracks disease progression and affects millions of patients worldwide, with AD alone impacting over 55 million people globally. The broad platform gives AC Immune S.A. more shots on goal than a single-asset bet.
- Tau covers vaccines, imaging, and small molecules
- Targets AD and other tauopathies
- Key long-term pipeline growth driver
AC Immune’s Star Pipeline Gains Momentum in Alzheimer’s and Tau
AC Immune S.A.'s Stars are led by ACI-24.060, now in Phase 2 for Alzheimer’s disease and Down syndrome, and ACI-35.030, which advanced from Phase 1b to Phase 2 in a high-growth tau field. PI-2620 Tau PET adds biomarker value through Life Molecular Imaging, while crenezumab still carries late-stage brand value if partnered interest holds.
| Asset | Status | BCG |
|---|---|---|
| ACI-24.060 | Phase 2 | Star |
| ACI-35.030 | Phase 2 | Star |
| PI-2620 Tau PET | Partnered | Star |
What is included in the product
Detailed Word Document
AC Immune S.A. BCG Matrix pinpoints pipeline stars, cash-draining bets, and divest-ready dogs to guide invest, hold, or cut decisions.
Editable Excel File
Quick BCG Matrix view of AC Immune S.A. to spot winners and cut portfolio noise fast
Reference Sources
Provides a clean source trail that boosts trust in AC Immune S.A. claims and speeds investor due diligence.
Cash Cows
Genentech Alliance
The Genentech alliance is a long-running antibody-discovery deal in neurodegeneration and still brings in milestone and research revenue in 2025, helping fund AC Immune S.A.’s R&D. It also gives strong external validation from a major pharma partner. Still, it is a Cash Cow, not a growth driver, because it has limited near-term commercial upside.
Janssen Partnership
Janssen is a cash cow-style partnership for AC Immune S.A. because it shares vaccine R&D work and pays deal-based fees, which cuts AC Immune S.A.'s direct cash burn. The collaboration also keeps pipeline funding partly off AC Immune S.A.'s balance sheet while Janssen carries a large share of development cost.
Life Molecular Imaging License
Life Molecular Imaging turns AC Immune S.A.'s tau PET tracer into a classic cash cow: one license can generate 3 cash streams-upfront, milestones, and royalties. That makes it one of the most monetizable assets in the portfolio, with low capital need versus internal development. In BCG terms, it is a mature, non-dilutive revenue engine tied to 1 of the most valuable neuroimaging franchises.
Biogen Collaboration
Biogen collaboration is a classic Cash Cow for AC Immune S.A.: a large-pharma Alzheimer’s deal that brings non-dilutive funding and shared lab know-how. Because the income is contract-based, it is steadier than product sales and helps smooth cash flow while AC Immune S.A. keeps advancing its pipeline.
- Large-pharma Alzheimer’s partnership
- Non-dilutive funding, no equity dilution
- Shared technical resources reduce burn
- Contract revenue is more predictable
WuXi Biologics Supply Tie-In
WuXi Biologics supply and development support lets AC Immune S.A. avoid heavy in-house capex for biologics manufacturing, so cash stays focused on clinical work. In a clinical-stage model, outsourced CMC (chemistry, manufacturing, and controls) cuts fixed costs and improves operating efficiency, which helps preserve runway. This makes the tie-in a cash-saving support asset, not a growth drag.
- Lower capex needs
- Higher operating efficiency
- Preserves clinical cash
- Reduces fixed-cost burden
AC Immune’s Cash Cows Keep 2025 Cash Flowing
AC Immune S.A.’s Cash Cows are partner-led assets that keep 2025 cash coming in with low internal spend. Genentech, Janssen, Biogen, and WuXi Biologics cut burn through shared R&D, fees, and outsourced CMC. Life Molecular Imaging is the clearest cash engine, with 3 monetization layers: upfronts, milestones, and royalties.
| Asset | 2025 role | Cash effect |
|---|---|---|
| Genentech | Cash Cow | Milestones, research revenue |
| Janssen | Cash Cow | Shared costs, lower burn |
| Life Molecular Imaging | Cash Cow | 3 revenue streams |
Preview Before You Purchase
AC Immune S.A. Reference Sources
The AC Immune S.A. BCG Matrix you’re previewing is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the complete, professionally formatted report ready to use.
What you see here is the final version of the BCG Matrix file. Once purchased, it will be available for immediate download with the same content and layout shown in the preview.
This preview reflects the real AC Immune S.A. BCG Matrix report you’ll get. It’s a ready-to-use document designed for clear strategic analysis and professional presentation.
Dogs
No Approved Products
As of end-2025, AC Immune S.A. still had no approved therapy, so this Dogs segment had zero product-sales base. The company stayed dependent on partnership cash, R&D funding, and equity markets, which is typical for a clinical-stage biotech without commercial revenue.
Clinical-Stage Only
AC Immune S.A. stayed a clinical-stage biotech, with no approved products and no product sales, so the Dogs bucket fits. Its assets were still in trials, which means R&D cash burn came before any revenue, unlike a mature pharma business with steady sales. That leaves its commercial position weak and highly dependent on funding, partnering, and trial progress.
No Recurring Blockbuster Revenue
AC Immune S.A. had no approved, high-volume product, so this was not a market-sales business. Revenue came mainly from collaboration and license income, not from a commercial franchise. That keeps share and growth low, which is why this sits in Dogs in the BCG matrix.
High R and D Burn
AC Immune S.A. sits in Dogs because its model depends on sustained R&D burn: late-stage trials, biomarker work, and manufacturing keep cash leaving before revenue catches up. In FY2025, the key risk is still the same: if clinical milestones slip, returns stay thin and valuation support remains weak.
- High R&D burn limits near-term cash return.
- Late-stage study delays weaken upside.
- Biomarkers and manufacturing add fixed cash drag.
Legacy Single-Asset Risk
AC Immune S.A.'s legacy single-asset risk is classic Dog territory: each program lives or dies on one trial readout and a partner's next move. In Alzheimer's, a miss can erase years of value fast, because sentiment and funding reset on data, not hope. That is why these underperforming assets stay low-growth and high-risk.
- Binary trial outcomes drive value.
- Partner decisions can end programs.
- Alzheimer's misses hit shares hard.
AC Immune Stays a Dog: No Sales, No Approved Drug, Ongoing Burn
AC Immune S.A. stays in Dogs because, as of end-2025, it still had no approved therapy and no product-sales base. FY2025 revenue came mainly from collaboration and license income, while R&D cash burn kept pressure on returns and funding.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Product sales | 0 |
| Revenue mix | Collaboration and license income |
Question Marks
ACI-7104.056 Preclinical
ACI-7104.056 is AC Immune S.A.'s anti-alpha-synuclein vaccine for Parkinson's disease, a market tied to about 10 million people worldwide and still growing with aging populations. But by end-2025 it was still preclinical, with no human efficacy data, so its commercial value remained unproven. That makes it a classic BCG Question Mark: high upside, high risk.
Tau Aggregation Inhibitors
AC Immune S.A.’s small-molecule Morphomer tau aggregation inhibitors target a core neurodegeneration pathway, which keeps the upside high. As of 2026, the program still lacked human proof of efficacy and had no marketed product, so its BCG position remains a Question Mark. In a market where Alzheimer’s care tops $1 trillion in global annual cost estimates, even modest tau benefit could matter.
TDP-43 Diagnostics
AC Immune S.A.'s TDP-43 diagnostics stay in the Question Mark bucket: discovery-stage only, with no clear 2025/2026 revenue stream yet. TDP-43 is tied to ALS, FTD, and related neurodegenerative diseases, so the long-term market is real, but the asset is still too early to judge scale. In BCG terms, this is a high-upside, high-risk bet that needs proof before it can move toward Star status.
Alpha-Synuclein Diagnostics
Alpha-synuclein diagnostics are early-stage question marks for AC Immune S.A.: they target Parkinson’s disease and related synucleinopathies, a patient pool already above 10 million worldwide. By end-2025, these assets still had low market share and no sales footprint, so they were value-creation bets, not cash contributors.
- Early-stage, pre-revenue diagnostics
- Parkinson’s and synucleinopathy focus
- End-2025: no sales footprint
NLRP3 Programs
AC Immune S.A.’s NLRP3 program sits in a high-interest neuroinflammation niche, but it is still a Question Mark because the work is discovery-stage and lacks clinical proof. In BCG terms, that means the target has upside if AC Immune converts it into a human readout, but today it still has 0 clinical validation to support market share. One-liner: promising biology, unproven asset.
- Discovery work, no clinical validation
- NLRP3 is a hot neuroinflammation target
- Still needs human data to de-risk
AC Immune’s Early Bets: Big Potential, No Proof Yet
AC Immune S.A.'s Question Marks are still early, pre-revenue bets: ACI-7104.056, Morphomer tau inhibitors, TDP-43 and alpha-synuclein diagnostics, and NLRP3. They offer big upside in markets like Parkinson's and Alzheimer's, but as of 2025/2026 they still lack human efficacy proof or commercial traction, so their BCG score stays high-risk, high-potential.
| Asset | 2025/2026 status | BCG |
|---|---|---|
| ACI-7104.056 | Preclinical | Question Mark |
| Morphomer tau | No human data | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.